Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Regencell Bioscience Holdings Ltd (RGC)
A forensic read on Regencell Bioscience Holdings Ltd built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Clean
Earnings quality
2
Forensic signals
-61.9%
ROE
$3.7B
Market cap
Regencell Bioscience Holdings Ltd earns a D (Weak — demands caution) forensic quality grade. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-58%Return on invested capital.Return on invested capital is -58% and slipping from -55% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+1253.8%/yrShare-count dilution.Diluted share count changed +3761% over the last 3 years to FY2025 (+1253.8%/yr). The count is GROWING — existing holders are being diluted. That's ~1253.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~3761%.
Key fundamentals
Debt / Equity0.62x
Free Cash Flow$-3.3M
Return on Equity-73.7%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Regencell Bioscience Holdings Ltd:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about RGC's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown